Bispecific Antibodies: Early Discovery to Preclinical Development

Bispecific Antibodies: Early Discovery to Preclinical Development Bispecific antibodies (BsAbs) enable diverse therapeutic MOAs such as retargeting cytotoxic effector cells, modulating receptor activity, and selectively recognizing pathogenic cells. However, advancing bsAbs from concept to preclinical candidates remains challenging, requiring comprehensive insights and technical expertise at every stage. This webinar will explore practical strategies for bsAb discovery, from lead identification and high-throughput (HTP) production to in vitro assays and in vivo studies. Through real-world case studies, we will highlight one-stop, modular solutions for bsAb design, screening, and functional characterization to support the development of next-generation bsAb therapeutics. In this webinar, you will learn: • Advanced antibody discovery platforms for biology-driven lead identification • Innovative Quick ‘n’ Clean platform for HTP bsAb production, unlocking optimal pairings rapidly • Comprehensive in vitro functional assays across T-cell engagers (TCEs), immune checkpoint inhibitors, and autoimmune diseases • Extensive in vivo efficacy models and well-established PK/PD/Tox platforms delivering time- and cost-effective solutions Bispecific antibodies (bsAbs) represent a significant advancement in biologic therapeutics, offering enhanced therapeutic efficacy through dual antigen targeting. However, advancing bsAbs from concept to preclinical candidates remains challenging, requiring comprehensive insights and technical expertise at every stage. In this webinar, our expert speaker will provide invaluable insights into end-to-end modular solutions centering around bsAb design, screening and functional characterization – supporting the development of next-generation bsAb therapeutics. 1. Learn how advanced antibody discovery platforms enable biology-driven lead identification 2. Explore how to produce bsAbs rapidly to unlock optimal pairings with the innovative Quick ‘n’ Clean platform 3. Hear about comprehensive in vitro functional assays across TCEs, immune checkpoint inhibitors and autoimmune diseases 4. Discover how well-established PK/PD/Tox platforms and extensive in vivo efficacy models can deliver effective solutions Dr. Macy Jin joined WuXi Biologics in April 2023 as a subject matter expert in biotherapeutic drug discovery. She brings over 20 years of experience from Wyeth/Pfizer, where she advanced from individual contributor to group leader of display platforms and project team leader in antibody discovery, with a focus on oncology, autoimmune and rare diseases. Macy has extensive technical expertise, including 10 years in hybridoma and over 10 years in display-based antibody discovery. She is a key inventor of phage panning and screening strategies that led to the discovery of Marstacimab (Hympavzi), the first FDA-approved anti-tissue factor pathway inhibitor (TFPI) antibody for Hemophilia in 2024.